LAKEWOOD, Colo., Feb. 16, 2023 /PRNewswire/ -- Today, Terumo Blood and Cell Technologies announces U.S. Food and Drug Administration (FDA) clearance and official launch of its IMUGARD ® WB Platelet ...
Promacta tended to boost platelet counts in patients with low-risk MDS, and helped those patients be independent of transfusions, too. Promacta (eltrombopag) improved platelet counts in patients with ...
We hypothesized that the combined use of leukoreduction and avoidance of infusion of ABO-incompatible antibodies or antigens would reduce both the need for HLA-matched platelets and the development of ...
Platelet transfusion thresholds in according bleeding risk and the presence of bleeding. WHO = World Health Organization. “In practice, we see all too often [that] prophylactic transfusion of ...
Conditioning regimens for hematopoietic SCT vary in degree or the intensity of myeloablative and immune suppressive potential. Some regimens incorporate total body radiation, whereas others use ...
Terumo Blood and Cell Technologies has announced US Food and Drug Administration (FDA) clearance and official launch of its IMUGARD(R)WB Platelet Pooling Set, which supports extended shelf life of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results